Increase of Antimyeloperoxidase Antineutrophil Cytoplasmic Antibody (ANCA) in Patients with Renal ANCA-associated Vasculitis: Association with Risk to Relapse

J Rheumatol. 2015 Oct;42(10):1853-60. doi: 10.3899/jrheum.141622. Epub 2015 Sep 15.

Abstract

Objective: The diagnostic values of antiproteinase 3 and antimyeloperoxidase tests using antineutrophil cytoplasmic antibodies (ANCA) are well established. Our study determined whether an increase in ANCA level was a predictor of disease flareup.

Methods: Our study included 126 patients with ANCA-associated renal vasculitis treated at 9 nephrology centers in Japan. The relationship between increased ANCA levels and relapse was assessed using time-dependent multivariate Cox regression models adjusted for clinically relevant factors. The outcome of interest was the time from remission to first relapse.

Results: During the observation period [median 41 mos, interquartile range (IQR) 23-66 mos], 118 patients (95.8%) achieved remission at least once. After achieving remission, 34 patients relapsed (21.7%). Time-dependent multivariate Cox regression models revealed that lung involvement (adjusted HR 2.29, 95% CI 1.13-4.65, p = 0.022) and increased ANCA levels (adjusted HR 17.4, 95% CI 8.42-36.0, p < 0.001) were significantly associated with relapse. The median time from ANCA level increase to relapse was 0.6 months (IQR 0-2.1 mos).

Conclusion: In our study, an increase in ANCA level during remission was associated with a risk of disease relapse. A rise in ANCA level may be useful for guiding treatment decisions in appropriate subsets of patients with ANCA-associated vasculitis.

Keywords: ANCA LEVEL; ANCA-ASSOCIATED VASCULITIS; ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES; GRANULOMATOSIS WITH POLYANGIITIS; MICROSCOPIC POLYANGIITIS; RELAPSE.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / blood*
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis / therapy*
  • Antibodies, Antineutrophil Cytoplasmic / blood*
  • Biomarkers / blood
  • Cohort Studies
  • Disease Progression
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Granulomatosis with Polyangiitis / blood*
  • Granulomatosis with Polyangiitis / physiopathology
  • Granulomatosis with Polyangiitis / therapy*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Kaplan-Meier Estimate
  • Kidney / pathology*
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Plasmapheresis / methods
  • Predictive Value of Tests
  • Prognosis
  • Proportional Hazards Models
  • Recurrence
  • Renal Dialysis / methods
  • Retrospective Studies
  • Risk Assessment
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Antineutrophil Cytoplasmic
  • Biomarkers
  • Immunosuppressive Agents